Essy Mozaffari

2.6k total citations
76 papers, 1.9k citations indexed

About

Essy Mozaffari is a scholar working on Infectious Diseases, Epidemiology and Ophthalmology. According to data from OpenAlex, Essy Mozaffari has authored 76 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 17 papers in Epidemiology and 16 papers in Ophthalmology. Recurrent topics in Essy Mozaffari's work include COVID-19 Clinical Research Studies (21 papers), Long-Term Effects of COVID-19 (15 papers) and Glaucoma and retinal disorders (13 papers). Essy Mozaffari is often cited by papers focused on COVID-19 Clinical Research Studies (21 papers), Long-Term Effects of COVID-19 (15 papers) and Glaucoma and retinal disorders (13 papers). Essy Mozaffari collaborates with scholars based in United States, United Kingdom and Germany. Essy Mozaffari's co-authors include Gail F. Schwartz, Beth Nordstrom, Harry A. Quigley, David S. Friedman, Gregory Reardon, Alexander M. Walker, Yehuda Carmeli, Matthew H. Samore, George M. Eliopoulos and Aastha Chandak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Essy Mozaffari

72 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Essy Mozaffari United States	22	901	439	381	358	291	76	1.9k
Andrew Atkinson Switzerland	19	76 0.1×	197 0.4×	130 0.3×	87 0.2×	260 0.9×	103	1.2k
Eyal Robenshtok Israel	27	84 0.1×	308 0.7×	126 0.3×	167 0.5×	812 2.8×	92	2.6k
Yung‐Feng Yen Taiwan	21	78 0.1×	466 1.1×	202 0.5×	60 0.2×	440 1.5×	99	1.4k
Anil Narang India	26	39 0.0×	141 0.3×	334 0.9×	297 0.8×	364 1.3×	101	1.9k
Brad Hutton United States	7	70 0.1×	1.4k 3.3×	130 0.3×	35 0.1×	347 1.2×	7	2.1k
James Spalding United States	24	20 0.0×	786 1.8×	297 0.8×	78 0.2×	546 1.9×	58	2.3k
Ana Ortega Spain	19	71 0.1×	419 1.0×	50 0.1×	107 0.3×	421 1.4×	76	1.4k
Daoud Al‐Badriyeh Qatar	16	136 0.2×	243 0.6×	127 0.3×	38 0.1×	174 0.6×	95	805
Aref A. Bin Abdulhak United States	15	21 0.0×	258 0.6×	114 0.3×	92 0.3×	377 1.3×	35	1.1k
Wing‐Wa Yan China	17	46 0.1×	608 1.4×	330 0.9×	33 0.1×	315 1.1×	38	1.9k

Countries citing papers authored by Essy Mozaffari

Since Specialization

Citations

This map shows the geographic impact of Essy Mozaffari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Essy Mozaffari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Essy Mozaffari more than expected).

Fields of papers citing papers by Essy Mozaffari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Essy Mozaffari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Essy Mozaffari. The network helps show where Essy Mozaffari may publish in the future.

Co-authorship network of co-authors of Essy Mozaffari

This figure shows the co-authorship network connecting the top 25 collaborators of Essy Mozaffari. A scholar is included among the top collaborators of Essy Mozaffari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Essy Mozaffari. Essy Mozaffari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berry, Mark, Amanda M. Kong, Roger Paredes, et al.. (2025). Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. Scientific Reports. 15(1). 27441–27441. 1 indexed citations

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2024). Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19. Clinical Infectious Diseases. 80(1). 63–71. 5 indexed citations

Mozaffari, Essy, Michele Bartoletti, Jakob J Malin, et al.. (2024). Evolution of the Evidence for the Management of COVID-19 in Hematologic Malignancies: A Systematic Literature Review of Remdesivir. Blood. 144(Supplement 1). 7750–7750.

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2024). Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores. Clinical Infectious Diseases. 79(Supplement_4). S167–S177. 1 indexed citations

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2024). Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of Comparative Effectiveness Research. 13(4). e230131–e230131. 2 indexed citations

Kalil, André C., Aastha Chandak, Luke Moore, et al.. (2024). Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19. Clinical Infectious Diseases. 79(Supplement_4). S160–S166.

Mozaffari, Essy, Aastha Chandak, Mark Berry, et al.. (2024). Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals. Clinical Infectious Diseases. 79(Supplement_4). S137–S148. 4 indexed citations

Mozaffari, Essy, Aastha Chandak, André C. Kalil, et al.. (2024). Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen. Open Forum Infectious Diseases. 11(6). ofae202–ofae202. 6 indexed citations

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2024). Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. Clinical Infectious Diseases. 79(Supplement_4). S149–S159. 3 indexed citations

10.

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2023). Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. Clinical Infectious Diseases. 77(12). 1626–1634. 34 indexed citations

11.

Mozaffari, Essy, Aastha Chandak, Robert Gottlieb, et al.. (2023). Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants. Open Forum Infectious Diseases. 10(10). ofad482–ofad482. 19 indexed citations

12.

Mozaffari, Essy, Aastha Chandak, Shuting Liang, et al.. (2021). Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. Open Forum Infectious Diseases. 9(1). ofab498–ofab498. 3 indexed citations

13.

Mozaffari, Essy, Aastha Chandak, Shuting Liang, et al.. (2021). Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clinical Infectious Diseases. 75(1). e450–e458. 79 indexed citations

14.

Mozaffari, Essy, et al.. (2021). PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study. Value in Health. 24. S121–S121. 1 indexed citations

15.

MacDonald, Thomas M., S. V. Morant, & Essy Mozaffari. (2007). Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Current Medical Research and Opinion. 23(11). 2765–2774. 6 indexed citations

16.

MacDonald, Thomas M., S. V. Morant, & Essy Mozaffari. (2007). Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. Journal of Human Hypertension. 21(12). 925–933. 12 indexed citations

17.

Nathwani, Dilip, Jim Z. Li, Richard J. Willke, et al.. (2004). An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. International Journal of Antimicrobial Agents. 23(4). 315–324. 19 indexed citations

18.

Schwartz, Gail F., Gregory Reardon, & Essy Mozaffari. (2003). Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. American Journal of Ophthalmology. 137(1). S13–S16. 76 indexed citations

19.

Bookhart, Brahim, et al.. (2002). Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.. PubMed. 8(10 Suppl). S255–61. 58 indexed citations

20.

Bullano, Michael, et al.. (2002). Rates of discontinuation and change of glaucoma therapy in a managed care setting.. PubMed. 8(10 Suppl). S262–70. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact